Home › New KEYTRUDA (pembrolizumab) Data Accepted for Presentation at SITC 2016 Annual Meeting
 

Keywords :   


New KEYTRUDA (pembrolizumab) Data Accepted for Presentation at SITC 2016 Annual Meeting

2016-11-07 13:00:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. First Presentation of Overall Survival Data in Patients with Advanced Bladder (Urothelial) Cancer from KEYNOTE-045 Study KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new data investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in patients with previously treated advanced urothelial cancer will be presented at the Society for Immunotherapy of Cancers (SITC) 31st Annual Meeting, Nov. 9-13. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orKim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: data meeting accepted annual

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
18.05Eastern North Pacific Tropical Weather Outlook
18.05Atlantic Tropical Weather Outlook
17.05House Republicans release farm bill draft
17.05House Republicans release farm bill draft
17.05Union forming stalled in US Mercedes-Benz
17.05Johnson & Johnson Acquires Atopic Dermatitis Treatment Biotech Company
17.05Register For Sustainable Cosmetics Summit
17.05Fewer crackers in Ritz boxes but price remains same
More »